Xention is developing novel therapies for the treatment of atrial fibrillation using its proprietary platform of ion channel drug discovery and development.
The Company is developing drug candidates that modulate two novel, but well characterised, ion channels and expects to develop breakthrough products in this area of huge unmet medical need.
In 2013 Xention partnered it lead drug with French pharmaceutical company Servier and his since progressed this programme into 2 Phase IIa studies.
Dr. Tim Brears
Unit 5, Quern House
Cambridgeshire CB22 5LD